Document is current
Any future updates will be listed below
-
Authors
Rodriguez, Maria Belen
Pulikottil-Jacob, Ruth
Heuer, Karli
Perez, Nancy Gabriela
Waggoner, Christine
Jussila, Diana
Gwaltney, Chad
Krupnick, Robert
Ng-Mak, Daisy
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 25 July 2024
Accepted: 1 September 2025
First Online: 20 November 2025
Declarations
:
: This study was approved by the Advarra Institutional Review Board (Columbia, MD, USA). All participants provided informed consent to participate in the study.
: Not applicable.
: MBR, and DN-M are employees and may hold stock and/or stock options in Sanofi. RP-J was an employee of Sanofi at the time of study conduct and may hold stock and/or stock options in Sanofi. KH, NGP, and RK are employees of IQVIA, which received professional service fees from Sanofi for conducting this research. RK is the principal investigator of the study. CW is a member of the Cure GM1 Foundation, which receives sponsorships from Sanofi for their annual conference, and is a non-salaried volunteer. DJ is a paid staff member of the National Tay-Sachs & Allied Diseases Association (NTSAD), which receives support from Sanofi in the form of educational and programmatic grants. CG is the principal consultant at Gwaltney Consulting, which received consulting fees from Sanofi.
